Source comparison
Sermorelin Anti-Aging Complete Guide 2026: Comparison of Administration Protocols
Clinical aging-intervention studies use subcutaneous administration exclusively. Intramuscular injection offers no bioavailability advantage and increases injection-site discomfort. The table below compares standard research dosing protocols. Low-Dose Daily 10
This comparison does not assign a generated winner or score.
- Clinical aging-intervention studies use subcutaneous administration exclusively. Intramuscular injection offers no bioavailability advantage and increases injection-site discomfort. The table below compares standard research dosing protocols.
- Low-Dose Daily
- 100–200 mcg/day
- Before bed (mimics natural nocturnal GH pulse)
- 2–4 ng/mL above baseline
- Used in initial aging-intervention studies to assess tolerability and minimal effective dose
- Safest starting point for baseline pituitary assessment. Allows titration based on IGF-1 response without overshooting physiological range
- Standard Daily
- 200–500 mcg/day
- Before bed
- 5–10 ng/mL above baseline
- Most common protocol in published anti-aging research; balances efficacy and side-effect profile
- Effective for most adults with moderate age-related GH decline; dose adjustments based on 4-week IGF-1 monitoring
- High-Dose Daily
- 500–1000 mcg/day
- Before bed or split AM/PM
- 10–20 ng/mL above baseline
- Reserved for severe GH deficiency or non-responders to standard dosing
- Higher doses don't guarantee proportional GH response due to receptor saturation; risk of desensitisation with chronic use
- Pulsed Protocol
- 300 mcg 3x/week
- Before bed on dosing days
- 6–12 ng/mL above baseline on injection days
- Emerging protocol to reduce receptor desensitisation while maintaining cumulative weekly exposure
- May preserve receptor sensitivity better than daily dosing; under-researched compared to daily protocols